A5079876604- Health Systems, Economic Evaluations, Quality of Life
- Economic and Financial Impacts of Cancer
- Cancer Genomics and Diagnostics
- Statistical Methods in Clinical Trials
- Pharmaceutical Economics and Policy
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- COVID-19 and healthcare impacts
- Biosimilars and Bioanalytical Methods
- Radiomics and Machine Learning in Medical Imaging
- Obesity, Physical Activity, Diet
- Cancer Treatment and Pharmacology
- Food Security and Health in Diverse Populations
- Chronic Lymphocytic Leukemia Research
- Infection Control and Ventilation
- Multiple Myeloma Research and Treatments
- Meta-analysis and systematic reviews
- Healthcare cost, quality, practices
- Social Media in Health Education
- Nutritional Studies and Diet
- Genetic factors in colorectal cancer
- CAR-T cell therapy research
- COVID-19 and Mental Health
University of California, San Francisco
2021-2025
Hospital Israelita Albert Einstein
2024
University Hospitals Birmingham NHS Foundation Trust
2023
Mission Bio (United States)
2023
University of California San Francisco Medical Center
2023
Maidstone Hospital
2021
Oklahoma State University Center for Health Sciences
2020
Oregon Health & Science University
2017-2020
AstraZeneca (Brazil)
2020
Oklahoma State University
2020
Immunotherapy checkpoint inhibitors have generated considerable interest because of durable responses in a number hitherto intractable tumor types.To estimate the percentage patients with cancer United States who are eligible for and respond to inhibitor drugs approved oncology indications by US Food Drug Administration (FDA).Retrospective cross-sectional study performed from June 2018 through October using publicly available data determine (1) demographic characteristics advanced or...
Immune checkpoint inhibitor (ICI) drugs have gained popularity in oncology because of their ability to boost a person’s immune response against cancer cells.1 We recently estimated that 43.6% US patients with are eligible for ICI therapy, and up 12.5% respond it.2 However, those were best-case estimates, postmarketing studies several these failed show improvement overall survival or progression-free survival.3 The Food Drug Administration (FDA) has revised some drug labels, future changes...
<h3>Importance</h3> Both novel and next-in-class cancer drugs have a role in oncology, but the relative development of each is understudied. <h3>Objective</h3> To characterize mechanisms action anticancer approved by US Food Drug Administration (FDA) between 2009 2020, noting how many approvals were based on new mechanism vs approvals. <h3>Design, Study, Participants</h3> This cross-sectional study included all FDA from January to December 2020. The drug was extracted labels. Supportive-care...
This retrospective review assesses the frequency of surrogate measures used for first time vs subsequent times in a cancer setting and surrogate's strength correlation with patient-centered outcomes.
Quality of life (QoL) is an important consideration in cancer medicine, especially because drugs are becoming more costly and may only result modest gains overall survival. However, there has been no descriptive analysis for the points at which QoL measured trials.To estimate prevalence studies that measure different see how many entirety a patient's life.This cross-sectional includes all articles on oncology clinical trials 3 highest-impact journals, published between July 2015 June 2018,...
Suboptimal treatment upon progression may affect overall survival (OS) results in oncology randomized controlled trials (RCTs). We aim to assess the proportion of reporting post-progression treatment.This cross-sectional analysis included two concurrent analyses. The first one examined all published RCTs anti-cancer drugs six high impact medical/oncology journals between January 2018 and December 2020. second studied US Food Drug Administration (FDA) approved during same period. Included...
Abstract Background The US Food and Drug Administration (FDA) has expanded the use of surrogate markers in drugs approved for oncology/hematology indications. This likely resulted a greater number approvals possibly coming to market faster, but it is unknown whether these also improve overall survival (OS) patients taking them. Methods We sought estimate percentage oncology that have shown OS cross‐sectional analysis FDA drug (2006–2023). searched data registration trials peer‐reviewed...
e14613 Background: Immune checkpoint inhibitors (ICIs) have notably changed the landscape of systemic treatment advanced and metastatic cancers in last decade. We previously estimated eligibility for responses to ICIs, but since then, there been multiple approvals additional indications. As such, we updated these estimates include all approvals, as December 2023. Methods: For eligibility, used death data from American Cancer Society’s Facts Figures. Deaths was a stand-in because therapies...
CDK4/6 inhibitors are oral agents inhibiting key molecules of the cell cycle regulation.In patients with endocrine receptor positive (ER+), human epidermal growth factor 2 negative (HER2-) breast cancer, combination therapy is an effective treatment in metastatic setting.Now, two studies adjuvant setting -MonarchE (2 years abemaciclib) and NATALEE (3 ribociclib)report invasive disease-free survival.Here, we re-evaluate these seminal trials.First, excess drop-out or loss-to-follow up occurred...
This cross-sectional study estimates all US Food and Drug Administration anticancer approvals in recent years evaluates if an association exists between their cost efficacy.
Objective Physicians have a large role in patient outcomes, and some questioned whether physician characteristics lead to better outcomes for the patient. Multiple studies been conducted on topic, leading variety of conclusions. To determine how frequently find favorable by pooled estimated effect. Methods: By searching PubMed, Web Science, Google Scholar, we identified that reported association between (age, experience, sex/gender, race/ethnicity, nationality, patient/physician...
Abstract In 2018, we estimated that eligibility for and response to immune checkpoint inhibitor (ICI) therapies were 44% 12%, respectively. Since these estimates published, there have been additional approvals. We sought provide updated of the percentage patients with advanced and/or metastatic cancers in US who are eligible respond inhibitors (ICIs). Using a cross‐sectional analysis (2011–2023) Food Drug Administration approvals (FDA) deaths reported by American Cancer Society, or ICI...
Increasingly, cost-effectiveness analyses are being done to determine the value of rapidly increasing oncology drugs; however, this assumes that these unbiased.To analyze characteristics studies and associated with whether an drug is found be cost-effective.This retrospective cross-sectional study included 254 for 116 drugs were approved by US Food Drug Administration from 2015 2020.Each was analyzed incremental ratio per quality-adjusted life year, funding study, authors' conflict interest,...